1) Call to Order
Charlene Fairfax, RPh

2) Minutes of Previous Meeting
Charlene Fairfax, RPh

3) Comments from Interested Parties*
Gidey Amare, RPh, MS

4) Clinical Drug Class Reviews
Ron Kavanagh, BS Pharm, PharmD, PhD

Acne Agents, Topical
Analgesics, Narcotics Long Acting &
Tramadol Like agents
Antibiotics, Inhaled
Antihistamines, Minimally Sedating
Antimigraine Agents
Bronchodilators, Beta Agonists
COPD Agents
Epinephrine, Self-Injected
Glucocorticoids, Inhaled
Intranasal Rhinitis Agents
Leukotriene Modifiers
NSAIDs
Ophthalmic Antibiotics
Ophthalmic Antibiotic-Steroid Combinations
Ophthalmics For Allergic Conjunctivitis
Ophthalmics, Anti-Inflammatory
Ophthalmics, Anti-Inflam-Immunomodulators
Ophthalmics, Glaucome Agents
Opiate Dependence Treatments
Otic Antibiotics
Otic Anti-inflammatories
PAH Agents, Oral And Inhaled
Skeletal Muscle Relaxants
Smoking Cessation Agents
Steroids, Topical High
Steroids, Topical Low
Steroids, Topical Medium
Steroids, Topical Very High
Stimulants and Related Agents

5) Executive Session (Committee Only)***
Charlene Fairfax, RPh
MMA Representatives

6) Final Recommendations of Preferred Drugs***
MMA Representatives

7) Announcement of Next Scheduled P&T Committee Meeting
Thursday, September 5th, 2019
Charlene Fairfax, RPh

8) Final Comments and Adjournment
Charlene Fairfax, RPh

*Individuals making oral presentations to the Committee will be limited to three (3) minutes
**Closed Session; ***Open Session